DDInter542 DDInter899
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
Dicoumarol {u} (Compound) downregulates {v} (Gene) P4HTM
Dicoumarol (Compound) resembles Phenprocoumon (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene)
Dicoumarol (Compound) downregulates P4HTM (Gene)